Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1994 1
1995 1
1999 1
2000 1
2002 1
2007 3
2008 2
2009 2
2011 2
2012 2
2013 1
2014 2
2015 5
2016 9
2019 1
2020 4
2021 2
2022 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
IDENTIFICATION OF POTENTIAL MARKERS FOR CUSHING DISEASE.
Broder MS, Chang E, Cherepanov D, Neary MP, Ludlam WH. Broder MS, et al. Among authors: ludlam wh. Endocr Pract. 2016 May;22(5):567-74. doi: 10.4158/EP15914.OR. Epub 2016 Jan 20. Endocr Pract. 2016. PMID: 26789346
Durable biochemical response and safety with oral octreotide capsules in acromegaly.
Samson SL, Nachtigall LB, Fleseriu M, Jensterle M, Manning PJ, Elenkova A, Molitch ME, Ludlam WH, Patou G, Haviv A, Biermasz NR, Giustina A, Strasburger CJ, Kennedy L, Melmed S. Samson SL, et al. Among authors: ludlam wh. Eur J Endocrinol. 2022 Oct 26;187(6):733-741. doi: 10.1530/EJE-22-0220. Print 2022 Dec 1. Eur J Endocrinol. 2022. PMID: 36173649 Free PMC article. Clinical Trial.
Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide.
Samson SL, Nachtigall LB, Fleseriu M, Gordon MB, Bolanowski M, Labadzhyan A, Ur E, Molitch M, Ludlam WH, Patou G, Haviv A, Biermasz N, Giustina A, Trainer PJ, Strasburger CJ, Kennedy L, Melmed S. Samson SL, et al. Among authors: ludlam wh. J Clin Endocrinol Metab. 2020 Oct 1;105(10):e3785-97. doi: 10.1210/clinem/dgaa526. J Clin Endocrinol Metab. 2020. PMID: 32882036 Free PMC article. Clinical Trial.
Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial.
Fleseriu M, Dreval A, Bondar I, Vagapova G, Macut D, Pokramovich YG, Molitch ME, Leonova N, Raverot G, Grineva E, Poteshkin YE, Gilgun-Sherki Y, Ludlam WH, Patou G, Haviv A, Gordon MB, Biermasz NR, Melmed S, Strasburger CJ. Fleseriu M, et al. Among authors: ludlam wh. Lancet Diabetes Endocrinol. 2022 Feb;10(2):102-111. doi: 10.1016/S2213-8587(21)00296-5. Epub 2021 Dec 22. Lancet Diabetes Endocrinol. 2022. PMID: 34953531 Clinical Trial.
Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands.
Fleseriu M, Molitch M, Dreval A, Biermasz NR, Gordon MB, Crosby RD, Ludlam WH, Haviv A, Gilgun-Sherki Y, Mathias SD. Fleseriu M, et al. Among authors: ludlam wh. Front Endocrinol (Lausanne). 2021 Mar 15;12:627711. doi: 10.3389/fendo.2021.627711. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33790860 Free PMC article. Clinical Trial.
40 results